| Title |
Safety and tolerability considerations in the use of sildenafil for children with pulmonary arterial hypertension
|
|---|---|
| Published in |
Drug, Healthcare and Patient Safety, December 2015
|
| DOI | 10.2147/dhps.s65571 |
| Pubmed ID | |
| Authors |
Andrew L Dodgen, Kevin D Hill |
| Abstract |
Sildenafil is a phosphodiesterase type-5 inhibitor approved for treatment of pulmonary arterial hypertension (PAH) in adults. Data from pediatric trials demonstrate a similar acute safety profile to the adult population but have raised concerns regarding the safety of long-term use in children. Interpretation of these trials remains controversial with major regulatory agencies differing in their recommendations - the US Food and Drug Administration recommends against the use of sildenafil for treatment of PAH in children, while the European Medicines Agency supports its use at "low doses". Here, we review the available pediatric data regarding dosing, acute, and long-term safety and efficacy of sildenafil for the treatment of PAH in children. |
X Demographics
The data shown below were collected from the profiles of 10 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 3 | 30% |
| Spain | 1 | 10% |
| Brazil | 1 | 10% |
| Nepal | 1 | 10% |
| Canada | 1 | 10% |
| Unknown | 3 | 30% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 4 | 40% |
| Practitioners (doctors, other healthcare professionals) | 3 | 30% |
| Science communicators (journalists, bloggers, editors) | 2 | 20% |
| Scientists | 1 | 10% |
Mendeley readers
The data shown below were compiled from readership statistics for 42 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 42 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 7 | 17% |
| Student > Bachelor | 5 | 12% |
| Researcher | 4 | 10% |
| Student > Postgraduate | 4 | 10% |
| Student > Ph. D. Student | 4 | 10% |
| Other | 5 | 12% |
| Unknown | 13 | 31% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 13 | 31% |
| Pharmacology, Toxicology and Pharmaceutical Science | 6 | 14% |
| Biochemistry, Genetics and Molecular Biology | 2 | 5% |
| Chemistry | 2 | 5% |
| Nursing and Health Professions | 1 | 2% |
| Other | 4 | 10% |
| Unknown | 14 | 33% |
Attention Score in Context
This research output has an Altmetric Attention Score of 15. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 February 2016.
All research outputs
#2,451,757
of 25,806,080 outputs
Outputs from Drug, Healthcare and Patient Safety
#14
of 162 outputs
Outputs of similar age
#38,868
of 397,846 outputs
Outputs of similar age from Drug, Healthcare and Patient Safety
#1
of 3 outputs
Altmetric has tracked 25,806,080 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 90th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 162 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.8. This one has done particularly well, scoring higher than 91% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 397,846 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 90% of its contemporaries.
We're also able to compare this research output to 3 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them